Genmab A/S (NASDAQ:GMAB) Short Interest Update

Genmab A/S (NASDAQ:GMAB) was the target of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 2,310,000 shares, an increase of 40.0% from the February 13th total of 1,650,000 shares. Approximately 0.4% of the company’s shares are short sold. Based on an average trading volume of 1,370,000 shares, the short-interest ratio is currently 1.7 days.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Genmab A/S by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after buying an additional 827 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after buying an additional 939 shares during the last quarter. Lindbrook Capital LLC lifted its position in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after buying an additional 950 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after buying an additional 1,051 shares during the last quarter. Finally, Eagle Asset Management Inc. lifted its position in shares of Genmab A/S by 10.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock worth $285,000 after buying an additional 1,121 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Up 1.4 %

Genmab A/S stock traded up $0.29 during trading on Monday, reaching $20.80. The stock had a trading volume of 1,008,499 shares, compared to its average volume of 905,576. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $31.02. The business has a 50 day moving average price of $21.24 and a 200 day moving average price of $22.38. The stock has a market cap of $13.76 billion, a PE ratio of 11.95, a P/E/G ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on GMAB shares. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Finally, BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.